DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Psoriatec (Anthralin) - News

 
 



News related to Psoriatec (Anthralin) and/or conditions it is approved for

Biologics Take Aim at Psoriasis Despite Worry Over Reactions
Source: Medscape Dermatology Headlines [2015.03.26]
The oral drug tofacitinib, typically prescribed for rheumatoid arthritis, is showing promise for the treatment of psoriasis, and new experimental agents are gaining ground.
Medscape Medical News

Boehringer Ingelheim's investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.03.25]
For the first time, Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066*.

Tough-to-Treat Psoriasis Responds to Anti-PDE4
Source: MedPage Today Allergy & Immunology [2015.03.25]
(MedPage Today) -- Response at 16 weeks maintained a full year in most cases.

Oral Otezla (apremilast) long-term safety and efficacy data in patients with moderate to severe plaque psoriasis presented
Source: Arthritis / Rheumatology News From Medical News Today [2015.03.24]
Celgene Corporation has announced that results from long-term efficacy and safety analyses of the ESTEEM phase III clinical trial program of Otezla® (apremilast) were presented at the 73rd...

Results from Phase III study evaluating oral otezla or injectable etanercept versus placebo in patients with moderate to severe plaque psoriasis
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.03.24]
Celgene Corporation has announced that results from its ongoing phase III LIBERATE trial evaluating Otezla® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4)...

Psoriasis and Tonsillectomy: A Real Head Scratcher
Source: MedPage Today Dermatology [2015.03.24]
(MedPage Today) -- Skin disease often improves after surgery but no one knows why.

IL-17 Inhibitor Clears Psoriasis More Often
Source: MedPage Today Dermatology [2015.03.22]
(MedPage Today) -- Brodalumab twice as likely to clear all lesions as ustekinumab.

Novel IL-23 Inhibitor Shows Promise in Psoriasis
Source: MedPage Today Dermatology [2015.03.22]
(MedPage Today) -- Interleukin-23 inhibitor has 'high efficacy, quiet safety signal.'

Psoriasis
Source: MedicineNet Actinic Keratosis Specialty [2015.01.28]
Title: Psoriasis
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 1/28/2015 12:00:00 AM

Psoriasis Pictures Slideshow: See Moderate to Severe Forms of this Common Skin Condition
Source: MedicineNet Actinic Keratosis Specialty [2015.01.15]
Title: Psoriasis Pictures Slideshow: See Moderate to Severe Forms of this Common Skin Condition
Category: Slideshows
Created: 2/3/2015 12:00:00 AM
Last Editorial Review: 1/15/2015 12:00:00 AM

Scalp Psoriasis
Source: MedicineNet alefacept Specialty [2014.05.20]
Title: Scalp Psoriasis
Category: Diseases and Conditions
Created: 7/24/2012 3:21:00 PM
Last Editorial Review: 5/20/2014 12:00:00 AM

Psoriasis Drug May Help Treat Type 1 Diabetes: Report
Source: MedicineNet alefacept Specialty [2013.09.24]
Title: Psoriasis Drug May Help Treat Type 1 Diabetes: Report
Category: Health News
Created: 9/23/2013 7:35:00 PM
Last Editorial Review: 9/24/2013 12:00:00 AM

Psoriasis Quiz: Test Your Medical IQ
Source: MedicineNet alefacept Specialty [2011.08.16]
Title: Psoriasis Quiz: Test Your Medical IQ
Category: MedicineNet Quiz
Created: 4/21/2011 3:23:00 PM
Last Editorial Review: 8/16/2011 1:27:34 PM

Remicade Phase 3 data show long-term psoriasis response
Source: The Doctors Lounge - Dermatology
Findings from two Phase 3 studies show high-level, sustained response with maintenance therapy.

Remsima (infliximab) accepted for restricted use in NHS Scotland by the Scottish Medicines Consortium
Source: Arthritis / Rheumatology News From Medical News Today [2015.03.11]
Patients in Scotland suffering from inflammatory conditions including rheumatoid arthritis (RA), Crohn's Disease (CD), ulcerative colitis (UC), and psoriasis will now have access to a new wave of...

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015